To the full analysis
Teva Pharmaceutical Industries stock: growth
TEVATeva Pharmaceutical Industries reported $17.26B in revenue for fiscal 2025, up 4.3% on the prior year, up 0.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
3.9%
per year from 2006 to 2025, per share 1.6%
Earnings (Annual rate)
5.1%
per year from 2006 to 2025, per share 2.9%
Free cash flow (Annual rate)
−1.9%
per year from 2006 to 2025, per share −4.1%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 0.7% | −1.3% | 3.9% |
| Revenue per share | −0.3% | −4.2% | 1.6% |
| Earnings | no data | −1.2% | 5.1% |
| Earnings per share | no data | −3.9% | 2.9% |
| Free cash flow | 12.5% | −13.3% | −1.9% |
| Free cash flow per share | 11.4% | −15.8% | −4.1% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $8.41B | $546M | $1.67B |
| 2007 | $9.41B | $1.95B | $1.27B |
| 2008 | $11.09B | $635M | $2.55B |
| 2009 | $13.9B | $2B | $2.65B |
| 2010 | $16.12B | $3.33B | $3.43B |
| 2011 | $18.31B | $2.76B | $3.08B |
| 2012 | $20.32B | $1.96B | $3.47B |
| 2013 | $20.31B | $1.27B | $2.21B |
| 2014 | $20.27B | $3.06B | $4.2B |
| 2015 | $19.65B | $1.59B | $4.77B |
| 2016 | $21.9B | $329M | $4.32B |
| 2017 | $22.39B | −$16.27B | $2.63B |
| 2018 | $18.85B | −$2.15B | $1.8B |
| 2019 | $16.89B | −$999M | $419M |
| 2020 | $16.66B | −$3.99B | $638M |
| 2021 | $15.88B | $417M | $236M |
| 2022 | $14.93B | −$2.45B | $1.04B |
| 2023 | $15.85B | −$559M | $842M |
| 2024 | $16.54B | −$1.64B | $749M |
| 2025 | $17.26B | $1.41B | $1.15B |
Revenue by segment
How Teva Pharmaceutical Industries Limited makes its money and how that has shifted. Names are as the company reports them.
- Product85%
- Distribution Service9%
- License4%
- Product and Service, Other2%
Figures as a table
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|
| Product | $14.35B | $13.83B | $12.77B | $12.98B | $14.43B | $14.61B | 84.6% |
| Distribution Service | $1.5B | $1.39B | $1.52B | $1.62B | $1.58B | $1.55B | 9% |
| License | $129M | $160M | $212M | $681M | $173M | $678M | 3.9% |
| Product and Service, Other | $680M | $500M | $428M | $570M | $365M | $423M | 2.5% |
| Total revenue | $16.66B | $15.88B | $14.93B | $15.85B | $16.54B | $17.26B | 100% |
Revenue by region
Where Teva Pharmaceutical Industries Limited generates its revenue.
- United States$9.2B53%
- Europe$5.0B29%
- International Markets$2.2B13%
- Other$869.0M5%
“Other” combines smaller regions with revenue the company does not assign to a region. The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| United States | $9.19B | 53.2% |
| Europe | $5.04B | 29.2% |
| International Markets | $2.16B | 12.5% |
| Other | $869M | 5% |
| Total revenue | $17.26B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Nov 2025)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.